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Abstract
Urinary tract infection (UTI) is one of the most common bacterial infections in humans, with uropathogenic Escherichia coli
(UPEC) the leading causative organism. UPEC has a number of virulence factors that enable it to overcome host defenses
within the urinary tract and establish infection. The O antigen and the capsular polysaccharide are two such factors that
provide a survival advantage to UPEC. Here we describe the application of the rpsL counter selection system to construct
capsule (kpsD) and O antigen (waaL) mutants and complemented derivatives of three reference UPEC strains: CFT073
(O6:K2:H1), RS218 (O18:K1:H7) and 1177 (O1:K1:H7). We observed that while the O1, O6 and O18 antigens were required for
survival in human serum, the role of the capsule was less clear and linked to O antigen type. In contrast, both the K1 and K2
capsular antigens provided a survival advantage to UPEC in whole blood. In the mouse urinary tract, mutation of the O6
antigen significantly attenuated CFT073 bladder colonization. Overall, this study contrasts the role of capsule and O antigen
in three common UPEC serotypes using defined mutant and complemented strains. The combined mutagenesis-
complementation strategy can be applied to study other virulence factors with complex functions both in vitro and in vivo.
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Introduction
Urinary tract infections (UTIs) are one of the most common
types of bacterial infection in humans. Approximately 150 million
cases of UTI are estimated to occur across the globe annually [1].
UTI occurs frequently in women; it is estimated that 40–50% of
adult healthy women experience at least one UTI episode in their
lifetime [2]. Catheterized patients, the elderly and children are also
at a higher risk for UTI [3–5]. If untreated, UTI may progress
from the bladder to the kidneys and even cause life-threatening
urosepsis. The estimated annual cost of treating UTI in the USA
alone is greater than $1.6 billion, thus emphasizing the global
economic burden these infections place on health care systems [2].
Uropathogenic Escherichia coli (UPEC) is the primary causative
organism in more than 80% of all UTI cases [6]. UPEC isolates
exhibit a high degree of genetic diversity, primarily due to the
possession of specialized virulence genes located on mobile genetic
elements called pathogenicity islands [7,8]. Although no single
virulence factor is uniquely definitive of UPEC, their ability to
cause symptomatic UTI is enhanced by adhesins (e.g. type 1, and
P fimbriae), toxins (e.g. hemolysin), iron acquisition systems and
cell surface polysaccharides [9–11]. The capsule and the O
antigen represent two cell-surface associated polysaccharides that
contribute to UPEC virulence [12–14]. These extracellular
polysaccharides protect UPEC against phagocytosis by immune
cells such as neutrophils and inhibit complement-mediated killing
[15,16].
Bacterial lipopolysaccharide (LPS) plays a primary role in
mediating UPEC resistance to the bactericidal activity of human
serum [17]. LPS consists of the highly conserved lipid A-core and
repeating O antigen subunits that differ greatly between strains
based on the sugar residues and their linkage patterns within the
repeating subunits [18]. More than 180 different serotypes have
been reported for E. coli [18,19], with some O antigen types such
as O1, O2, O4, O6, O7, O8, O16, O18, O25, and O75 being
common among UPEC strains [20]. This variation is imparted by
differences in the genes that encode for glycosyltransferase
enzymes that modify O antigen structure. The lipid A-core and
the O antigen subunits are assembled in separate pathways that
come together for ligation at the inner membrane [21]. WaaL is a
conserved O antigen ligase and the only known membrane
enzyme implicated in the ligation of pre-assembled undecaprenyl-
diphosphate (Und-PP)-linked O antigen to lipid A-core oligosac-
charide [22]. E. coli K-12 waaL deletion mutants are unable to cap
the lipid A-core and are therefore disrupted in the expression of O
antigen at the cell surface [23].
Like the O antigen, there is also significant variation in the E.
coli capsule. More than 80 distinct types of E. coli capsule have
been identified, with four major groups defined based on genetic
assembly, biochemistry and physical attributes [24]. The group 2
capsular polysaccharides have mostly been associated with UPEC
strains [12,25]. The role of the capsule in protecting UPEC from
phagocytosis has been defined [26,27], however, its role in
resistance to serum-mediated killing is unclear, with several
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conflicting reports in the literature [28–31]. Understanding the
role of the capsule in UPEC serum resistance is further
complicated by the use of multiple strains with different O antigen
and capsule types. For example, a multi-strain study by Stawski
et al. found that the contribution of capsule to serum resistance
varied between strains and ranged from being important to having
no protective role [32]. The genes involved in capsule production
are located in the kpsFEDUCS operon [24,33]. KpsD is a 60 kDa
outer membrane protein involved in the export of group 2
capsular polysaccharides across the outer membrane [34].
Mutation of kpsD results in the loss of surface expression of the
capsule and accumulation of polysaccharide within the periplas-
mic space [35].
Given the importance of O antigen and capsule in UPEC
virulence, we studied the function of these polysaccharides in three
well-characterized UPEC strains (CFT073, RS218 and 1177)
bearing different O and K antigens. We employed a recently
described counter-selection strategy based on streptomycin-kana-
mycin resistance (mediated by the rpsL and neo genes, respectively)
for the mutation of single genes and the subsequent repair of these
mutations to generate complemented strains [36]. This enabled us
to generate a defined set of wild-type (WT), mutant and
complemented strains that were used to test the contributions of
O antigen and capsule to UPEC virulence. Our study is the first to
demonstrate the use of the rpsL-neo counter-selection system in
UPEC, and shows that the O antigen is the major polysaccharide
responsible for UPEC serum resistance and survival in the mouse
urinary tract.
Results
Construction of capsule and O antigen insertion mutants
A prerequisite for the rpsL-neo counter-selection system is that
the bacterial strain should be streptomycin resistant (StrepR) and
that this resistance is the direct effect of a mutation within the rpsL
gene. Streptomycin resistance is a recessive trait and in the
presence of both WT and mutant alleles, the strain is sensitive to
streptomycin (StrepS) [37]. This trait can be exploited for the rapid
mutation and repair of mutated genes, and a schematic outline of
the strategy we employed is presented in Figure 1. StrepR
derivatives of the UPEC strains CFT073 (O6:K2), 1177 (O1:K1)
and RS218 (O18:K1) were generated spontaneously by sequential
plating on increasing concentrations of streptomycin. These
StrepR strains (CFT073Strep, 1177Strep, RS218Strep) were then
transformed with pRedET, a temperature sensitive expression
plasmid harboring the l-Red recombinase genes. Mutation of the
waaL (O antigen) and kpsD (capsule) genes in the pRedET-
containing strains was performed by insertional inactivation
following homologous recombination between the bacterial
chromosome and the rpsL-neo cassette flanked by 50 bp homology
regions and subsequent growth on kanamycin LB-agar. These
mutants, which became sensitive to streptomycin due to the
presence of a functional rpsL gene, were referred to as
CFT073waaL, CFT073kpsD, 1177waaL, 1177kpsD, RS218waaL
and RS218kpsD, respectively.
Generation of complemented strains
To repair the mutation and generate complemented strains,
pRedET was re-introduced into the mutant strains and they were
transformed with a 100 bp oligonucleotide that contained the
same sequence as the WT strain in the regions flanking the point
of insertion of the rpsL-neo cassette (Figure 1). The re-constructed
WT strains were selected based on resistance to streptomycin, as
loss of a functional rpsL gene reverted them to a StrepR phenotype.
These strains were referred to as CFT073waaLC, CFT073kpsDC,
1177waaLC, 1177kpsDC, RS218waaLC and RS218kpsDC, respec-
tively. In summary, we therefore generated a series of O antigen
and capsule mutants, as well as repaired/complemented strains, in
three UPEC strains with different O and K antigens. Hereon, all
references to WT strains denote the StrepR derivatives of CFT073,
E. coli 1177 and RS218, respectively.
Phenotypic characterization of capsule mutants and
complements
The K1 phage assay was used to detect the presence of a K1
capsule on the surface of UPEC strains 1177 and RS218 (Figure 2).
In this assay, the 1177 and RS218 WT strains were killed upon
encountering the phage due to its specific attachment to the K1
capsule and subsequent lytic replication life-cycle. In contrast, the
kpsD mutants exhibited normal growth beyond the streak line,
indicating a loss of K1 capsule expression and thus resistance to
phage killing. A WT phenotype was fully restored in the
complemented strains. In separate experiments, counter-current
immunoelectrophoresis using K2 antiserum was used to detect K2
capsule on the surface of CFT073. Capsular extracts from
CFT073, CFT073kpsD and CFT073kpsDC were electrophoresed
against K2 antisera. A precipitin band was observed for CFT073
and CFT073kpsDC, while this was absent in CFT073kpsD. Taken
together, these results confirm the K1 or K2 capsule phenotype of
the three mutated and complemented UPEC strains.
Phenotypic characterization of O antigen mutants and
complemented strains
The waaL gene encodes an O antigen ligase and its mutation
abolishes the attachment of the O antigen to the LPS core,
resulting in a rough phenotype. In order to phenotypically
characterize the waaL mutants and their complemented strains,
LPS extracts were prepared from standardized late log phase
cultures, separated by TSDS-PAGE and viewed by silver staining
(Figure 3). As expected, due to their different O types, the LPS
banding patterns from WT CFT073, 1177 and RS218 varied. E.
coli 1177 (O1) possessed an even distribution of short, medium and
long O antigen side chains, while CFT073 (O6) and RS218 (O18)
possessed predominantly short and long O antigen side chains.
Disruption of the waaL gene resulted in complete loss of the bands
corresponding to the O antigen subunits from all strains, with only
the lipid A-core detected. In each of the complemented strains, the
O antigen-banding profile was restored to WT.
O antigen is the major determinant of serum resistance
To compare the relative contribution of O antigen and capsule
to UPEC serum resistance we tested our WT, mutant and
complemented strains in a serum survival assay. In this assay,
bacterial survival was measured as colony forming units (CFU)
before and after incubation with pooled normal human sera. As
expected, the WT strains CFT073, 1177 and RS218 were resistant
to killing by human serum (Figure 4). In contrast, the
CFT073waaL, 1177waaL and RS218waaL mutants were all highly
sensitive to human serum and displayed a high serum sensitivity
index (SSI; P,0.05, paired t test). This phenotype reverted back to
WT (i.e. resistant) in each of the respective complemented strains.
The contribution of the capsule to serum resistance was less clear.
The CFT073kpsD mutant was most sensitive (SSI = 2, P=0.046),
while RS218kpsD displayed reduced sensitivity (SSI = 1, P=0.027).
Complementation of the kpsD mutation in CFT073kpsD and
RS218kpsD resulted in reversion to a WT resistance phenotype.
The 1177kpsD mutant, on the other hand, was completely resistant
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to serum killing. The E. coli K12 strain MG1655 was used as a
control for the integrity of serum, and was completely killed in all
assays. All the strains were resistant to heat-inactivated normal
human sera (data not shown). Taken together, our data show that
O antigen is the major determinant of serum resistance in the
UPEC strains tested. Furthermore, given that 1177 and RS218 are
K1 capsule type, the observed difference in their serum sensitivities
indicate that the contribution of the capsule to serum resistance is
closely linked to O antigen serotype.
UPEC survival in whole blood
The most well-characterized virulence-related role of capsular
expression in UPEC relates to bacterial resistance to uptake and
killing by phagocytes such as neutrophils and monocytes [15]. In
view of this, and the data from the above assays that showed a less
clear contribution of the capsule to serum resistance compared to
O antigen, we performed a series of whole blood killing assays.
These assays incorporate both of the cell types relevant to UPEC
phagocytosis. In these experiments, the CFT073kpsD and
1177kpsD mutants displayed significantly enhanced sensitivity to
killing by whole blood compared to their respective WT
counterparts (Figure 5; P,0.05, independent samples t test); in
contrast, RS218 WT was so sensitive to killing in this assay that the
data on the kpsD mutants could not be interpreted. Complemen-
tation of the kpsD mutation in CFT073kpsD and 1177kpsD restored
survival to WT levels. Given that 1177 and RS218 both produce a
K1 capsule, these data suggest that there may be differences in the
composition of their K1 antigen, or that the role of the K1 capsule
in resistance to killing by whole blood is strongly linked to O
antigen type, as observed in serum killing assays.
The O6 antigen and K2 capsule are required for
colonization of the mouse urinary tract
Analysis of plasmid-based complemented strains in vivo is
challenging as it is difficult to ensure consistent expression of the
cloned gene or maintenance of the plasmid in the pathogen during
infection. A major advantage of the counter selection strategy
described here is that complementation is performed by repair of
the mutated chromosomal gene, and thus the complemented
strains can be tested in vivo. In order to demonstrate this, we
analyzed the CFT073 WT, capsule and O antigen mutant and
complemented strains in a mouse UTI model. Experiments were
performed as mixed competition assays, whereby mice were
inoculated with a 1:1 mix of CFT073:CFT073kpsD, CFT073kpsD:
CFT073kpsDC, CFT073:CFT073waaL or CFT073waaL:CFT073-
waaLC and the number of colonizing bacteria was calculated at
18 h post infection. In these assays, both the capsule and O
antigen mutants were significantly outcompeted by the WT and
complemented strains in colonization of the bladder (Figure 6;
P,0.05). No significant colonization of the kidneys was observed
(data not shown); this is consistent with previous data from our
laboratory using C57BL/6 mice [38–41]. Taken together, these
data demonstrate that the O6 antigen has a major impact on the
colonization of the urinary tract by CFT073, and that the K2
capsular antigen, while less important, also contributes to this
phenotype.
Figure 1. Schematic representation of the mutagenesis strategy utilizing rpsL counter selection. A 100 bp conserved region (shown as
patterned region in WT sequence) was selected for the kpsD and waaL; StrepR strains harboring the pRedET plasmid were transformed with PCR
product consisting of the rpsL-neo cassette flanked by 50 bp regions homologous to sequences on either side of the chosen point of insertion;
double cross-over events during homologous recombination make the mutant strains StrepS KanR due to integration of the rpsL-neo cassette; for
complementation, mutant strains were transformed with 100 bp oligonucleotides bearing the same sequence as the WT across the region of
insertion; complemented strains were again StrepR due to loss of the rpsL-neo cassette and restoration of the parental genotype; streptomycin
resistant (StrepR), streptomycin sensitive (StrepS), kanamycin resistant (KanR). The methodology depicted in this figure is a modification of the rpsL
counter-selection technique previously used for site-directed mutagenesis in bacterial artificial chromosomes [57–59].
doi:10.1371/journal.pone.0094786.g001
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Discussion
The polysaccharide capsule and O antigen are well-described
UPEC virulence determinants that contribute to resistance against
host defenses. Specific O and K types are associated with UPEC
infection, often to different degrees depending on the serotype of
the strain. In this study, we investigated the role of different O and
K antigens in mediating resistance to serum and whole blood, and
colonization of the urinary tract, using a novel set of WT, mutant
and complemented strains.
Gene disruption in bacteria using l-Red mediated homologous
recombination is a widely used and highly efficient technique [42].
In this method, the mutation of a gene or set of genes is attained by
insertional inactivation using an antibiotic cassette that can
subsequently be removed by FLP-mediated recombination to
leave a characteristic scar sequence at the target site. Several
modifications have been made to l-Red recombineering to
improve recombination frequency that can otherwise be a major
limitation in certain applications. These include using transfor-
mation amplimers with large flanking regions [43], the removal of
endogenous nucleases from the host strain [44], and the use of
three-way overlapping PCR methods that negate the need for
multiple intermediary cloning steps [45,46]. Complementation of
a specific mutation, a common procedure used to prove the
function of a gene and fulfill Koch’s postulates, is normally
achieved in trans by introduction of the relevant gene into the cell
on a plasmid. This approach, while effective, can be complicated
by the need for antibiotic selection to maintain the plasmid
[47,48], differences in copy number of the complemented gene
due to its location on a plasmid [49] and differences in expression
of the complemented gene [50]. These issues are often
compounded when complementation is attempted in an animal
infection model. Another approach for complementation involves
the use of a transducing phage to repair the mutation on the
chromosome [51]. This involves the replacement of up to 40 kb of
the chromosomal region surrounding the target gene, and also
requires the use of a strain-specific phage. A different allelic
exchange strategy using suicide vectors can be employed when
several rounds of modification are required, however problems
such as the need for large flanking regions to facilitate
recombination, loss of temperature sensitivity of the vector or
drastically reduced recombination efficiency due to mismatched
bases with target DNA sequences make this method less than ideal
when dealing with non genome-sequenced clinical isolates [52].
Transposable elements also provide an alternative to l-Red
Figure 2. Phenotypic characterization of capsule mutants
(kpsD) and complemented (kpsDC) UPEC strains. A) Agar slab
showing K1 phage reactions of 1177 and RS218 strains with CFT073
(expressing K2 antigen) as negative control; dashed lined through the
center denotes line of phage suspension. Wild-type and complemented
strains expressing K1 antigen are lysed by the phage and exhibit
inhibited growth upon crossing the line of phage suspension. Growth
of capsule mutants and the negative control strain is unaffected. B)
Agarose gel showing precipitin bands arising from cross-linking of K2
antigen and antisera post electrophoresis. CFT073 WT and capsule
complement show a positive reaction; no band is observed for the kpsD
mutant due to loss of surface expression of the K2 antigen.
doi:10.1371/journal.pone.0094786.g002
Figure 3. Analysis of lipopolysaccharide profiles by silver staining. Silver stained LPS profiles from strains listed below the gels. LPS banding
patterns vary according to serotype; CFT073:O6 (A), E. coli 1177:O1 (B), RS218:O18 (C). Wild-type, O antigen mutant (waaL) and its complemented
strain (waaLC) are ordered from left to right. The thick band at the bottom represents the lipid A core and is intact in all the strains. The bands stacked
on top of the core represent different O antigen side chains of different lengths that disappear in the waaL mutant strains. Banding patterns are
restored in the complemented strains and appear to be the same as the WT.
doi:10.1371/journal.pone.0094786.g003
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mediated homologous recombination. Transposition based strat-
egies involving transposons such as Tn-5 and Tn-7, as well as their
derivatives, have been used successfully to generate transposon
mutant libraries [53,54] for site specific tagging [55] and for the
generation of transcriptional/translational target gene fusions [56].
The rpsL counter selection system has been used previously for
the modification of bacterial artificial chromosomes in viral and
eukaryotic systems [57-59]. In E. coli, this system has been used in
conjunction with loxP to generate markerless chromosomal
deletions [60] and to introduce point mutations at specific sites
on the chromosome [36]. Here, we have demonstrated its
application in the construction of mutant and complemented
UPEC strains. The method for complementation was highly
efficient, and only required the use of a 100 base oligonucleotide
that matched the target region. Since the complementation
method stably generates the parental genotype without the need
for a selectable marker, complemented strains can be used in
animal infection experiments without antibiotic selection. This
method is analogous to that previously described for sacB, another
widely used counter selectable marker [61]. However, an
advantage of rpsL counter selection is that unlike the sacB system,
it can still be used in strains containing a native ColE1 replicon
Figure 4. UPEC survival in human serum. Bacteria (approximately 46108 CFU/ml) were incubated in fresh human serum for 90 min and colony
counts were used to determine serum sensitivity index (SSI) for each strain, shown at the top of the graph. SSI of 0 represents a resistant strain;
1,2,3,4,5 represent equivalent reduction in log values of colony forming units (CFU/ml) post incubation with serum. The WT strains CFT073, 1177 and
RS218 were resistant; CFT073waaL, 1177waaL and RS218waaL mutants were all highly sensitive to human serum (SSI; P,0.05, paired t test) and the
complemented strains (waaLC) were resistant. CFT073kpsD and RS218kpsD mutants displayed reduced sensitivity (SSI = 2 and 1, respectively);
complemented strains (kpsDC) were resistant. The 1177kpsD mutant was completely resistant to serum killing.
doi:10.1371/journal.pone.0094786.g004
Figure 5. Survival of UPEC CFT073 (A) and 1177 (B) WT, mutant and complemented strains in whole blood killing assays. Bacteria
were incubated in fresh whole blood for 3–5 h and colony counts were used to compare survival phenotypes of mutants and complemented strains
to the WT parents. Fitness of the CFT073 and 1177 capsule (kpsD) mutants was significantly impaired compared to the WT, and was restored
completely in the respective capsule complemented (kpsDC) strains. The survival data for the RS218 WT derivatives could not be analyzed due to the
high sensitivity of WT strain to killing by whole blood. P values, as determined by the independent samples, t test were as follows: # 0.038, * 0.042.
doi:10.1371/journal.pone.0094786.g005
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[62,63]. A disadvantage of the rpsL counter selection system is that
it requires the generation of a spontaneous streptomycin resistant
derivative of the strain to be studied, and it cannot be applied
directly to strains with an existing streptomycin resistance cassette
[64,65]. Mutations in the native rpsL gene have also been shown to
result in a fitness cost on E. coli growth, with the decline in
bacterial fitness dependent on the type of rpsL mutation and the
carbon source available in the medium [66,67]. Thus, this issue
needs to be considered when comparing the virulence of knockout
and complemented strains where one is StrepR and the other is
StrepS. In this study, we used spontaneously generated StrepR
derivatives of each parent strain (referred to as WT for simplicity),
as well as mutants and repaired/complemented strains generated
from these StrepR derivatives. Although we did observe a slight
decrease in exponential growth rate for the StrepR strains, several
of our mutants (which were StrepS) still exhibited clear phenotypes
with respect to serum resistance, whole blood killing and bladder
colonization. Furthermore, our spontaneous CFT073 StrepR
derivate (CFT0073Strep) colonized the C57BL/6 mouse bladder
at a similar level to that we have reported previously for CFT073
[38,68].
Three UPEC strains with different O and K antigens were used
to demonstrate the application of the rpsL counter selection system.
For UPEC, the potential influence of waaL deletion and disruption
of expression of O antigen on virulence is undefined except for a
recent study that showed waaL was required for efficient
colonization of mouse bladder [14]. Disruption of the waaL gene
has been shown to result in uncapped lipid A-core due to the
absence of a functional O antigen ligase [23,69]. Our waaL
mutants had a similar lipid A-core region, while the characteristic
O antigen was absent (and restored in complemented strains). The
role of O antigen in mediating serum resistance in multiple
bacterial pathogens has been extensively reported in the literature
[32,43,70,71]. Our results demonstrate that the O1, O6 and O18
antigens are important for survival in serum. This is consistent
with previous studies on the O18 antigen, which has been
extensively studied in the context of neonatal meningitis strains
[72–74]. Our results for the O1 and O6 antigens, while expected,
represent to the best of our knowledge the first demonstration of
this phenotype in well-defined mutant and complemented strains.
Mutation of the kpsD gene resulted in mutants lacking any
surface exposed K antigen, and this was restored by complemen-
tation. In our experiments, the K2 capsule contributed to the
resistance of CFT073 against the bactericidal activity of human
serum. A study by Buckles et al. has shown the importance of the
K2 capsule in UTI pathogenesis and its role in preventing
complement mediated killing [31]. Notably, the serum sensitivity
index for the K2 mutant in our study was significantly lower than
its corresponding O antigen mutant (P,0.01). However, both of
the strains were resistant to heat-inactivated normal human sera
indicating a role for complement attack that depends at least in
part, on the presence of O antigen. There are conflicting reports in
the literature about the importance of K1 capsule in effecting
bacterial survival in serum. A study by Leying et al. has suggested
that K1 expression is a prerequisite for serum resistance [28].
However, the mutants used were not defined and complementa-
tion was not described. Likewise, Kim et al. reported that the K1
capsule plays a more important role than the O18 antigen in
establishing bacteremia in a neonatal rat meningitis model [29]. In
contrast, an earlier report concluded that in a similar animal
model, the K1 capsule, while important for establishing menin-
gitis, had no effect on bacterial survival in serum [75]. Several
other reports have corroborated these findings [30,76,77]. Both
the RS218 and 1177 strains used in our study produce a K1
capsule. We observed that while the absence of the capsule renders
RS218 slightly susceptible to the bactericidal activity of serum, it
had no significant effect on 1177. We also analyzed UPEC survival
in whole blood to elucidate the role of capsule in protecting against
whole blood killing. Survival of the CFT073 and 1177 capsule
mutants was significantly impaired, which is similar to the role of
K5 capsule antigen that mediates resistance to phagocytosis in
UPEC [15]. The RS218 WT strain exhibited a poor survival rate
and its corresponding mutants could not be analyzed by this assay.
Thus, the importance of the K1 capsule in mediating serum
resistance and survival in whole blood is variable, and possibly
linked to the O antigen type and other factors such as hemolysin
Figure 6. Fitness of CFT073 capsule (kpsD) and O antigen (waaL)
mutants during in vivo competition with CFT073 WT and
corresponding complemented (kpsDC, waaLC) strains. C57B/L6
mice were infected transurethally with a 1:1 mixture of CFT073kpsD and
CFT073 WT or CFT073kpsDC; CFT073waaL and CFT073 WT or
CFT073waaLC. (A) Each marker represents LOG10 total CFU recovered
from each mouse per 0.1 g of bladder tissue. Lines connect data points
for the same mouse, and horizontal bars represent median values. (B)
Each marker represents the LOG10 competitive index calculated for each
individual mouse; competitive indices are the ratio of the mutant 0.1 g
of bladder tissue to that of WT or complemented strain. Dashed lines
represent hypothetical competitive index of 1 (LOG101 = 0), which
indicates no difference in fitness between the two strains. Horizontal
bars represent group medians, and each competition group had 6 to 8
mice. All mutants were significantly outcompeted by CFT073 WT or
their respective complemented strains for bladder colonization
(P,0.05). The O6 antigen was significantly more important than the
K2 capsular antigen for bladder colonization (P,0.05).
doi:10.1371/journal.pone.0094786.g006
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[78], outer membrane proteins (OmpA, OmpC) [79,80] and
plasmid-encoded virulence factors (TraT, Iss) [81,82].
A key advantage of the rpsL counter selection strategy is that
mutants can be complemented and studied in vivo. To demonstrate
this, the ability of the CFT073 capsule and O antigen mutant
strains to cause disease in a mouse UTI model was analyzed. We
observed that both the K2 and O6 mutants were outcompeted by
the WT and the complemented strains in bladder colonization
during mixed infection challenges. However, based on competitive
index the O6 antigen was significantly more important for disease
pathogenesis than the K2 capsule. These results confirm the
importance of the O6 antigen and, to some extent, the K2
capsular antigen, as colonization factors of the mouse urinary
tract. The results are also consistent with a recent report
demonstrating that restoration of the O-antigen producing
capacity of the E. coli K12 strain MG1655 was sufficient for it to
kill Caenorhabditis elegans at rates comparable to other pathogenic
bacteria [83]. The expression of O antigen and capsule on the
bacterial surface can also affect the function of other virulence
factors [84,85]. Differences in the role of other UPEC K capsular
antigens during infection have also been described previously. For
example, the K15 antigen is important for virulence but not for
serum resistance in a neonatal mouse UTI model [86], while a
protective role for O4 but not for the K54 antigen has been
described during colonization of the mouse urinary tract [87].
The O antigen and capsule are well known virulence factors of
UPEC, however the interplay between common O and K antigens
remains to be assessed using defined mutant and complemented
strains. Here we have described a strategy to make single gene
mutants and their complements that can be analyzed in vitro and in
Table 1. Bacterial strains used in this study
Strain Relevant Characteristics Reference
E. coli K12 strains
MG1655 OR:K- [94]
MC1061hsdR hsdR, mcrB, araD, 139_(araABCleu) 7679 DlacX74 galU galK rpsL thi [47,95]
UPEC WT strains
CFT073 O6:K2 [96]
E. coli 1177 O1:K1 [97]
RS218 O18:K1 [98]
Streptomycin resistant strains
CFT073 StrepR CFT073rpsL, StrepR This study
E. coli 1177 StrepR E.coli 1177rpsL, StrepR This study
RS218 StrepR RS218rpsL, StrepR This study
CFT073 strains
CFT073(pRedET) CFT073rpsL (pRedET), StrepR, TetR This study
CFT073kpsD CFT073kpsD::rpsl-neo, KanR This study
CFT073kpsD(pRedET) CFT073kpsD::rpsl-neo(pRedET), KanR, TetR This study
CFT073kpsDC Re-constructed CFT073 from CFT073kpsD, StrepR This study
CFT073waaL CFT073waaL::rpsl-neo, KanR This study
CFT073waaL(pRedET) CFT073waaL::rpsl-neo(pRedET), KanR, TetR This study
CFT073waaLC Re-constructed CFT073 from CFT073waaL, StrepR This study
E. coli 1177 strains
1177(pRedET) 1177rpsL (pRedET), StrepR, TetR This study
1177kpsD 1177kpsD::rpsl-neo, KanR This study
1177kpsD(pRedET) 1177kpsD::rpsl-neo(pRedET), KanR, TetR This study
1177kpsDC Re-constructed 1177 from 1177kpsD, StrepR This study
1177waaL 1177waaL::rpsl-neo, KanR This study
1177waaL(pRedET) 1177waaL::rpsl-neo(pRedET), KanR, TetR This study
1177waaLC Re-constructed 1177 from 1177waaL, StrepR This study
RS218 strains
RS218(pRedET) RS218rpsL (pRedET), StrepR, TetR This study
RS218kpsD RS218kpsD::rpsl-neo, KanR This study
RS218kpsD(pRedET) RS218kpsD::rpsl-neo(pRedET), KanR, TetR This study
RS218kpsDC Re-constructed RS218 from RS218kpsD, StrepR This study
RS218waaL RS218waaL::rpsl-neo, KanR This study
RS218waaL(pRedET) RS218waaL::rpsl-neo(pRedET), KanR, TetR This study
RS218waaLC Re-constructed RS218 from RS218waaL, StrepR This study
doi:10.1371/journal.pone.0094786.t001
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vivo. With the aid of mutant and complemented strain sets we have
shown that the surface expression of the O1, O6 and O18 antigens
and to a lesser extent, the K2 antigen, are important for bacterial
survival in human serum. O1, O6, K1 and K2 antigens were all
found to provide a survival advantage in the presence of whole
blood. The O6 antigen was shown to be more important than the
K2 antigen for colonization of the mouse bladder. The strategy
described herein can be applied to study other virulence factors
with complex functions and thus avoid the use of plasmid-based
systems for complementation.
Materials and Methods
Ethical approval
This study was carried out in strict accordance with the
recommendations in the Animal Care and Protection Act
(Queensland, 2002) and the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes (7th edition,
2004). Approval for mouse infection studies was obtained from the
University of Queensland Animal Ethics Committee (SCMB/
471/09/NHMRC (NF)). Approvals for the collection of human
blood for serum sensitivity and whole blood killing assays were
obtained from the University of Queensland Medical Research
Ethics Committee (2008001123) and the Griffith University
Human Research Ethics Committee (MSC/18/10/HREC),
respectively.
Bacterial strains and growth conditions
The UPEC strains used in this study are listed in Table 1. Wild-
type clinical isolates and their derivatives were routinely cultured
at 28uC or 37uC on solid or in liquid Luria-Bertani (LB) medium
[88] supplemented with the appropriate antibiotics: streptomycin
(Strep, 100 mg/ml), kanamycin (Kan, 50 mg/ml), tetracycline (Tet,
5 mg/ml). Streptomycin-resistant derivatives of UPEC strains
CFT073, 1177 and RS218 were generated by sequential growth
on increasing concentrations of streptomycin (10 mg/ml, 25 mg/
ml, 50 mg/ml and 100 mg/ml).
DNA manipulations and genetic techniques
Oligonucleotides used in this study were sourced from Sigma-
Aldrich (Australia). Plasmid pRedET and the rpsL-neo template
were obtained from the Counter selection BAC modification kit
(GeneBridges). Isolation of plasmid DNA was carried out using the
QIAprep Spin Miniprep Kit (Qiagen). All polymerase chain
reactions were performed using Taq DNA polymerase (New
England Biolabs) under standard conditions except for reactions
requiring high fidelity, in which case Phusion DNA polymerase
(Thermo Scientific) was used. DNA sequencing for mutant and
complement validation was performed using the Big Dye v3.1 kit
(Applied Biosystems) at the Australian Equine Genetics Research
Centre, University of Queensland.
Construction of capsule and O antigen insertion mutants
Primers were designed using Vector NTI Advance 10 software
(Invitrogen). Due to the unavailability of the RS218 and E. coli
1177 genome sequence, sequences of kpsD and waaL genes from
UPEC strains CFT073, APEC01, 536 and UTI89 were aligned to
identify 100 bp regions of complete sequence conservation. These
sequences were incorporated as the 50 bp homology regions at the
59 end of the forward and reverse knockout primers. The 39 end of
the primers contained the 24 base sequences specified in the
Counter selection BAC modification kit (GeneBridges), which
were used to amplify the rpsL-neo cassette. The primer sequences
used are as follows: kpsD forward (F): TCCAACGTCAACGTC-
TACGCCTCCTTATTACAGGCGCAGCCAGTAAAAGTGG-
CCTGGTGATGATGGCGGGATCG; kpsD reverse (R): ACGT-
CACACCGCCATACAGACCAGGATTACGCACAAATCCG-
GTCACGTACTCAGAAGAACTCGTCAAGAAGGCG; waaL F:
CGCGTGCAGCCATATTAGTGTTTCCATTCTTTGCG-
TTACTATTAATCGTAGGCCTGGTGATGATGGCGGGA-
TCG; waaL R: ATAAAACAATATAACTTATAATTAATTCG-
CTTATTAATATAACTATCCATTCAGAAGAACTCGTCAA-
GAAGGCG. Screening primers were designed at least 70 bp
upstream and downstream of the homology regions, respectively.
Their sequences are as follows: kpsD screen F: GATGGTGCGT-
TACAGGTTGATC; kpsD screen R: CCGCGCTTGACCA-
CAATATC; waaL screen F: CAACAGCAGGCTACATCATCC;
waaL screen R: CTTCATACATTGCCAGACGG. Streptomycin
resistant UPEC strains CFT073, 1177 and RS218 were trans-
formed with pRedET by electroporation and selected in the
presence of tetracycline. These strains were then grown at 28uC to
an optical density at 600nm (OD600 nm) of 0.3, induced with
L-arabinose (0.3% w/v) for approximately 1 h to allow expression
of the recombinase genes, and then electroporated with the rpsL-
neo cassette bearing the 50 bp homology regions. Mutants that
were streptomycin sensitive (StrepS) and kanamycin resistant
(KanR) were identified and insertion of the rpsL-neo cassette within
the kpsD and waaL genes, respectively, was confirmed by PCR and
sequencing.
Complementation of capsule and O antigen insertion
mutants
Plasmid pRedET was re-introduced into the CFT073, 1177,
and RS218 waaL and kpsD mutants, respectively. To repair the
waaL and kpsD mutations, these strains were prepared as described
above and transformed with 2 mM single-stranded 100 base
oligonucleotides comprising a sequence identical to the WT strain
in the mutated region (kpsD:TCCAACGTCAACGTCTACG-
CCTCCTTATTACAGGCGCAGCCAGTAAAAGTGTACG-
TGACCGGATTTGTGCGTAATCCTGGTCTGTATGGC-
GGTGTGACGT; waaL:CGCGTGCAGCCATATTAGTGTT-
TCCATTCTTTGCGTTACTATTAATCGTAATGGATAGT-
TATATTAATAAGCGAATTAATTATAAGTTATATTGTTT-
TAT). Repair of the specific waaL or kpsD mutation in StrepR
colonies was confirmed by PCR screening and sequencing.
K1 phage assay
K1 phage solution was sourced from the Statens Serum Institut
(Denmark). The cross-brush method recommended by the
manufacturer was used to determine the presence of K1 antigen
[89]. Briefly, a vertical line of phage suspension was streaked
across an agar plate and allowed to dry. Horizontal lines of
overnight E. coli broth cultures were then streaked from left to right
across the phage suspension and plates were incubated at 37uC for
12 h. Inhibited growth or complete killing of bacteria after
crossing the phage suspension was deemed a positive reaction. A
negative reaction, in the absence of K1, was characterized by
normal bacterial growth across the entire bacterial streak. CFT073
WT strain with K2 capsule was used as a negative control for the
assay.
Counter current immunoelectrophoresis
E. coli diagnostic K2 antisera (Statens Serum Institut, Denmark)
was used to detect the presence of the K2 antigen. Capsule
extracts were made according to manufacturer guidelines. Briefly,
the bacterial cells from an agar plate were suspended in 1 ml
phosphate buffered saline (PBS) (pH 7.4) and incubated at 60uC
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for 20 min. The cell suspension was then centrifuged for 30 min at
14,000 rpm and the supernatant transferred to a fresh tube and
heated for 1 h at 95uC. Extracts were then diluted in PBS (1:50)
for electrophoresis. A 1.5% agarose gel was applied to a glass plate
with 2 rows of wells and a distance of 5 mm between each row.
15 ml of K2 antisera and diluted capsule extracts were loaded at
the anode and cathode ends, respectively. Counter-current
immunoelectrophoresis was performed for 70 min at 80 V in 1X
TAE buffer. A precipitin band between the wells demonstrated the
presence of a K2 capsule.
LPS isolation and silver staining
LPS was extracted as described previously by West et al. [90].
Tricine-SDS PAGE (TSDS PAGE) was used to obtain a high
resolution of LPS. Gels were cast with a 16.5% resolving phase
containing 4 M urea, overlaid with a 4% stacking phase. A two-
buffer system was used for electrophoresis as previously described
[91]. Electrophoresis was performed in the Mini-PROTEAN gel
apparatus (BioRad) at 50 V for 30 min and then at 150 V for
70 min. A modified silver staining method originally described by
Tsai and Frasch [92] was used to view LPS bands. Gels were
transferred to a glass tray and fixed overnight (40% ethanol, 5%
glacial acetic acid) at room temperature. The fixing solution was
replaced with an oxidizing solution (40% ethanol, 5% glacial
acetic acid, 0.7% periodic acid) and incubated for 7 min. Gels
were washed repeatedly in copious amounts of milliQ water and
then stained (20 mM sodium hydroxide, 0.4% ammonium
hydroxide, 0.7% silver nitrate) for 10 min. The staining solution
was removed and gels were incubated in the dark in a developing
solution (0.02% formaldehyde, 0.26 mM citric acid) until distinct
bands were visible. Gels were then washed in water to stop the
reaction.
Serum killing assay
Overnight bacterial cultures were washed in PBS and then
standardized to a final OD600 = 0.8 (approximately 4610
8 CFU/
ml). A volume of 50 ml of each standardized culture was mixed
with an equal volume of PBS and serially diluted for colony counts
on agar to enumerate CFU prior to serum treatment (t = 0 min).
Fresh blood was collected in EDTA-free vacutainer tubes on the
day of the assay from two healthy human donors who gave
informed consent. The same donors were used for all assays in
order to reduce serum variability. Blood was allowed to clot for
15 min and the tubes were centrifuged at 1500 g for 10 min. A
volume of 50 ml of each standardized culture (approximately
36107 CFU) was mixed with an equal volume of pooled human
sera, mixed and incubated for 90 min at 37uC. All experiments
were performed in triplicate. Colony counts were used to
enumerate bacterial cells post treatment (t = 90 min). E. coli
MG1655 was used as a serum sensitive control strain. All the
strains were tested similarly in a parallel assay using heat-
inactivated normal human sera (Millipore). Strains showing at
least a log10 difference (i.e. 10-fold) in CFU/ml were deemed to
have altered sensitivity to serum as compared to WT. Serum
sensitivity indices (SSI) were calculated according to these
differences. Paired samples t tests were performed on CFU/ml
values at the two time points (0 min and 90 min) to determine
statistical significance.
Whole blood killing assay
Approximately 104 colony forming units (CFU) of UPEC
prepared from a late exponential phase culture in LB were added
to 1.5 ml of whole blood collected from a healthy human
volunteer using plasma preparation tubes (PPT) containing
9.0 mg K2EDTA (BD Vacutainer, NJ, USA). The infected
cultures were incubated rolling at 37uC and after 3–5 h diluted
blood samples were plated in triplicate onto agar to enumerate the
surviving bacteria. The survival rate was calculated as a
percentage of the starting inoculum ([CFU (at a given time
point)/CFU (at the start)]6100) and P values were determined
using the independent samples t test.
Mouse model of UTI
The mouse model of UTI described by Roos et al. (2006) was
used in this study [93]. Female C57BL/6 mice (8–10 weeks) were
purchased from the University of Queensland Animal Facility and
housed in sterile cages with ad libitum access to sterile water. All
strains used in this experiment were enriched for type 1 fimbriae
expression after 3 passages under static conditions. Bacterial
cultures were prepared by overnight static growth in LB broth; all
strains were strongly positive for type 1 fimbriae expression as
determined by yeast cell agglutination. For competitive (mixed
infection) assays, inocula contained 1:1 strain mixtures of
CFT073kpsD and CFT073 WT (group 1) or CFT073kpsDC
(complement; group 2); CFT073waaL and CFT073 WT (group
3) or CFT073waaLC (group 4). An inoculum of 20–40 ml,
containing 56108 CFU of bacteria in PBS was injected directly
into the bladder of each mouse. Urine was collected from mice
18 h after challenge following which they were euthanized by
cervical dislocation. Bladders were then excised aseptically,
weighed, and homogenized in PBS. Urine and bladder homog-
enates were serially diluted in PBS and plated onto streptomycin
and kanamycin-containing LB agar for colony counts. The two
strains in each group were differentiated by their resistance to
streptomycin (WT and complements) or kanamycin (kpsD and
waaL mutants). Significance was determined using the two-tailed
Wilcoxon matched pairs test on CFU/ml urine, or CFU/0.1 g
bladder tissue using Prism6 (GraphPad). P values ,0.05 were
considered significant.
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